This article is a commentary on:
Identification of IFN-Induced Transmembrane Protein 1 With Prognostic Value in Pancreatic Cancer Using Network Module-Based Analysis
Xinxiao Li1†
Renba Liang
Liu Yang- 1Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
- 2Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
A Commentary on
Identification of IFN-Induced Transmembrane Protein 1 With Prognostic Value in Pancreatic Cancer Using Network Module-Based Analysis
By Wu L, Zhu X, Yan D, Tang M, Ma C and Yan S (2021). 11:626883. doi: 10.3389/fonc.2021.626883
The human interferon (IFN)-induced transmembrane protein 1 (IFITM1), also called Leu13 or CD225, is a 17-kDa cell-surface membrane protein in the IFN-stimulated genes (ISGs) protein family (1). IFITM1 was initially identified as a leukocyte membrane surface antigen involving in signal transduction in lymphocytes, such as antiproliferative and homotypic adhesion signaling (2, 3). Additionally, IFITM1 was regarded as a modulator of immunity and antiviral activity (1). Recently, with great interest we read a study “Identification of IFN-Induced Transmembrane Protein 1 With Prognostic Value in Pancreatic Cancer Using Network Module-Based Analysis” in Frontiers in Oncology (4), revealing that the expression level of IFITM1 was increased in pancreatic cancer. Patients with IFITM1 overexpression had poor survival, and IFITM1 was one of the independent prognostic factors for overall survival. Moreover, down-regulation of IFITM1 significantly suppressed the tumorigenicity of pancreatic cancer cells (4). In addition, increasing evidence have demonstrated that IFITM1 was also upregulated in numerous tumor tissues as well as cancer cell lines, such as colorectal cancer (5), gastroesophageal adenocarcinoma (6), gastric cancer (7, 8), hepatocellular carcinoma (9), lung cancer (10), breast cancer (11, 12), head and neck cancer (13, 14), gallbladder carcinoma (15), ovarian cancer (16), glioma (17), and nasopharyngeal carcinoma (18). Overexpression of IFITM1 enhanced cell proliferation, invasion, metastasis, angiogenesis, and therapeutic resistance, including endocrine therapy, chemotherapy, and radiotherapy resistance of tumors. Mechanically, IFITM1 exerted cancer-promoting effects through regulating serval pathways, including EGFR/SOX2 (10), JAK/STAT (11), and CAV-1 (19). These findings suggest that pharmacological or genetic inhibition of IFITM1 maybe a potential and novel therapeutic approach for tumors.
Author Contributions
Study concept and design, XL. Data analysis, methodology, drafting manuscript, RL. Review and editing, supervision, LY. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Siegrist F, Ebeling M, Certa U. The Small Interferon-Induced Transmembrane Genes and Proteins. J Interferon Cytokine Res (2011) 31:183–97. doi: 10.1089/jir.2010.0112
2. Takahashi S, Doss C, Levy S, Levy R. TAPA-1, the Target of an Antiproliferative Antibody, Is Associated on the Cell Surface With the Leu-13 Antigen. J Immunol (1990) 145(7):2207–13.
3. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 Signal Transducing Complex of Human B Lymphocytes Includes the Target of Antiproliferative Antibody-1 and Leu-13 Molecules. J Immunol (1992) 149(9):2841–50.
4. Wu L, Zhu X, Yan D, Tang M, Ma C, Yan S. Identification of IFN-Induced Transmembrane Protein 1 With Prognostic Value in Pancreatic Cancer Using Network Module-Based Analysis. Front Oncol (2021) 11:626883. doi: 10.3389/fonc.2021.626883
5. Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A, et al. Identification of the IFITM Family as a New Molecular Marker in Human Colorectal Tumors. Cancer Res (2006) 66:1949–55. doi: 10.1158/0008-5472.CAN-05-2731
6. Borg D, Hedner C, Gaber A, Nodin B, Fristedt R, Jirstrom K, et al. Expression of IFITM1 as a Prognostic Biomarker in Resected Gastric and Esophageal Adenocarcinoma. Biomark Res (2016) 4:10. doi: 10.1186/s40364-016-0064-5
7. Lee J, Goh SH, Song N, Hwang JA, Nam S, Choi IJ, et al. Overexpression of IFITM1 has Clinicopathologic Effects on Gastric Cancer and Is Regulated by an Epigenetic Mechanism. Am J Pathol (2012) 181:43–52. doi: 10.1016/j.ajpath.2012.03.027
8. Lee HR, No HK, Ryu CJ, Park HJ. Brahma-Related Gene 1-Associated Expression of 9–27 and IFI-27 Is Involved in Acquired Cisplatin Resistance of Gastric Cancer Cells. Mol Med Rep (2013) 8:747–50. doi: 10.3892/mmr.2013.1576
9. Wu L, Tang Q, Yin X, Yan D, Tang M, Xin J, et al. The Therapeutic Potential of Adipose Tissue-Derived Mesenchymal Stem Cells to Enhance Radiotherapy Effects on Hepatocellular Carcinoma. Front Cell Dev Biol (2019) 7:267. doi: 10.3389/fcell.2019.00267
10. Yang YG, Koh YW, Sari IN, Jun N, Lee S, Phi L, et al. Interferon-Induced Transmembrane Protein 1-Mediated EGFR/SOX2 Signaling Axis Is Essential for Progression of non-Small Cell Lung Cancer. Int J Cancer (2019) 144:2020–32. doi: 10.1002/ijc.31926
11. Lui AJ, Geanes ES, Ogony J, Behbod F, Marquess J, Valdez K, et al. IFITM1 Suppression Blocks Proliferation and Invasion of Aromatase Inhibitor-Resistant Breast Cancer In Vivo by JAK/STAT-Mediated Induction of P21. Cancer Lett (2017) 399:29–43. doi: 10.1016/j.canlet.2017.04.005
12. Alam U, Kennedy D. G3BP1 and G3BP2 Regulate Translation of Interferon-Stimulated Genes: IFITM1, IFITM2 and IFITM3 in the Cancer Cell Line MCF7. Mol Cell Biochem (2019) 459:189–204. doi: 10.1007/s11010-019-03562-3
13. Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y, et al. IFN-Induced Transmembrane Protein 1 Promotes Invasion at Early Stage of Head and Neck Cancer Progression. Clin Cancer Res (2008) 14:6097–105. doi: 10.1158/1078-0432.CCR-07-4761
14. Yang J, Li L, Xi Y, Sun R, Wang H, Ren Y, et al. Combination of IFITM1 Knockdown and Radiotherapy Inhibits the Growth of Oral Cancer. Cancer Sci (2018) 109:3115–28. doi: 10.1111/cas.13640
15. Li D, Yang Z, Liu Z, Zou Q, Yuan Y. DDR2 and IFITM1 Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas. Pathol Oncol Res (2019) 25:157–67. doi: 10.1007/s12253-017-0314-3
16. Kim NH, Sung HY, Choi EN, Lyu D, Choi HJ, Ju W, et al. Aberrant DNA Methylation in the IFITM1 Promoter Enhances the Metastatic Phenotype in an Intraperitoneal Xenograft Model of Human Ovarian Cancer. Oncol Rep (2014) 31:2139–46. doi: 10.3892/or.2014.3110
17. Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon WS, et al. Knockdown of Interferon-Induced Transmembrane Protein 1 (IFITM1) Inhibits Proliferation, Migration, and Invasion of Glioma Cells. J Neurooncol (2011) 103:187–95. doi: 10.1007/s11060-010-0377-4
18. Guo Y, Zhu XD, Qu S, Li L, Su F, Li Y, et al. Identification of Genes Involved in Radioresistance of Nasopharyngeal Carcinoma by Integrating Gene Ontology and Protein–Protein Interaction Networks. Int J Oncol (2012) 40:85–92. doi: 10.3892/ijo.2011.1172
Keywords: IFITM1, cancer, treatment, progress, target
Citation: Li X, Liang R and Yang L (2021) Commentary: Identification of IFN-Induced Transmembrane Protein 1 With Prognostic Value in Pancreatic Cancer Using Network Module-Based Analysis. Front. Oncol. 11:707516. doi: 10.3389/fonc.2021.707516
Received: 10 May 2021; Accepted: 08 July 2021;
Published: 20 July 2021.
Edited by:
Shilpa S. Dhar, University of Texas MD Anderson Cancer Center, United StatesReviewed by:
Ken Hirasawa, Memorial University of Newfoundland, CanadaCopyright © 2021 Li, Liang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Liu Yang, yangliugd@126.com
†These authors have contributed equally to this work